Solstice Pain Relieving

Camphor, Menthol, Methyl Salicylate


Madison One Acme Inc
Human Otc Drug
NDC 55614-310
Solstice Pain Relieving also known as Camphor, Menthol, Methyl Salicylate is a human otc drug labeled by 'Madison One Acme Inc'. National Drug Code (NDC) number for Solstice Pain Relieving is 55614-310. This drug is available in dosage form of Patch. The names of the active, medicinal ingredients in Solstice Pain Relieving drug includes Camphor (synthetic) - 3.1 g/100g Menthol - 6 g/100g Methyl Salicylate - 10 g/100g . The currest status of Solstice Pain Relieving drug is Active.

Drug Information:

Drug NDC: 55614-310
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Solstice Pain Relieving
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Camphor, Menthol, Methyl Salicylate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Madison One Acme Inc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Patch
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CAMPHOR (SYNTHETIC) - 3.1 g/100g
MENTHOL - 6 g/100g
METHYL SALICYLATE - 10 g/100g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 29 Jul, 2019
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 16 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:MADISON ONE ACME INC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1793147
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:5TJD82A1ET
L7T10EIP3A
LAV5U5022Y
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
55614-310-066 PATCH in 1 BOX (55614-310-06) / 9 g in 1 PATCH29 Jul, 2019N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose external analgesic external analgesic external analgesic

Product Elements:

Solstice pain relieving camphor, menthol, methyl salicylate camphor (synthetic) camphor (synthetic) menthol menthol methyl salicylate salicylic acid hydrogenated polydecene (550 mw) pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate) liquid petroleum styrene/acrylamide copolymer (mw 500000)

Indications and Usage:

Uses for the temporary relief of minor aches and pains of muscles and joints due to: simple backache arthritis strains bruises sprains

Warnings:

Warnings for external use only

Do Not Use:

Warnings for external use only

When Using:

When using this product avoid contact with the eyes or mucous membranes do not bandage tightly do not apply heat to the area in the form of heating pads, hot water bottles, or lamps (doing so increases the risk of serious burns) avoid placing on extremely hairy areas of skin to avoid irritation upon removing the patch

Dosage and Administration:

Directions adults and children 3 years of age and older: clean and dry affected area remove the protective film from the patch apply patch to affected area not more than 3 to 4 times daily remove patch from the skin after at most 8-hour application wet patch with warm water before removing from the skin children under 3 years of age: consult your physician

Stop Use:

Stop use and ask a doctor if condition worsens symptoms persist for more than 7 days symptoms clear up and occur again within a few days excessive irritation of the skin develops nausea, vomiting, abdominal discomfort, diarrhea, or skin rash occurs you feel actual pain or experience blistering or burning after application (it is normal to feel a warming or cooling sensation) when using for pain of arthritis: pain persists for more than 10 days redness is present in conditions affecting children under 12 years of age

Adverse Reactions:

Report any unexpected side effects from the use of this product to the fda medwatch program

Package Label Principal Display Panel:

Solstice pain relieving patch large camphor 3.1%, menthol 6.0%, methyl salicylate 10% ndc 55614-310-06 6 patches, each patch 5.67 in x 3.62 in (14.4 cm x 9.2 cm) 6ct box

Further Questions:

Questions or comments? (888) 221-3496 m-f 9 am to 5 pm you may also report serious side effects to this phone number


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.